Mineralys Therapeutics Inc
MLYSNASDAQStock · Data from SEC EDGAR 13F · Held by 4 of 87 tracked investors
Mineralys Therapeutics Inc at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation15
- Growth–
- Profitability25
- Quality15
- Debt100
- Stability31
- ✓It has more cash than debt.
- ✓The analysts' average target is 119% above the price.
- !The company is loss-making: net profit is negative.
The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.
Is the stock expensive?
ExpensiveThe company has no earnings, so the P/E cannot be calculated.
- P/E
- –
- P/S
- –
- EV/EBITDA
- -3.4×
Is the company growing?
–Too few years to compare. Last year –.
Does it make money?
Loss-makingNet margin: 0.0%.
Is it financially healthy?
Yes- Cash
Earnings results
| Quarter | Reported | EPS | Analyst estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | 11 Aug 2026 | -2.85 | -0.57 | -400% |
| Mar 2026 | 6 May 2026 | -0.47 | -0.51 | +7.8% |
| Dec 2025 | 12 Mar 2026 | -0.40 | -0.57 | +29.8% |
| Sep 2025 | 10 Nov 2025 | -0.52 | -0.66 | +21.2% |
EPS is earnings per share. The surprise is the difference against the analysts' consensus. Source: Nasdaq, in dollars.
Chart MLYS
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
4PF Pale Fire Capital Pale Fire Capital SE | 1.17% |
PT Paul Tudor Jones Tudor Investment Corp | 0.03% |
JS Jim Simons Renaissance Technologies | 0.01% |
IE Israel Englander Millennium Management | 0.01% |
Frequently asked questions
How much is Mineralys Therapeutics Inc (MLYS) stock?
Mineralys Therapeutics Inc shares trade at $21.13, +2.77% over the last trading day. The price is delayed.
What is the market cap of Mineralys Therapeutics Inc?
The market cap of Mineralys Therapeutics Inc is about $1.9B.
Which big investors hold Mineralys Therapeutics Inc?
According to the latest 13F filings, 4 of 87 tracked investors hold Mineralys Therapeutics Inc, for example Pale Fire Capital, Paul Tudor Jones, Jim Simons.
When will Mineralys Therapeutics Inc report its next results?
The next earnings report of Mineralys Therapeutics Inc is expected on 9 Nov 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.